Tenaya Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
TNYA$0.39+9.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
|---|---|---|---|---|---|
| 3.1 | Composite Amended and Restated Certificate of Incorporation of the Tenaya Therapeutics, Inc. | 10-Q | 001-40656 | 3.1 | 8-9-2023 |
| 3.2 | Amended and Restated Bylaws of Tenaya Therapeutics, Inc. | 8-K | 001-40656 | 3.1 | 3-21-2023 |
| 4.1 | Specimen common stock certificate of the Registrant. | S-1/A | 333-257820 | 4.2 | 7-26-2021 |
| 4.2* | Description of Securities of the Registrant. | ||||
| 4.3 | Warrant to Purchase Stock | 10-Q | 001-40656 | 4.1 | 11-6-2024 |
| 4.4 | Form of Series A Warrant to Purchase Common Stock | 8-K | 001-40656 | 4.1 | 3-4-2025 |
| 4.5 | Form of Series B Warrant to Purchase Common Stock | 8-K | 001-40656 | 4.2 | 3-4-2025 |
| 4.6 | Form of Warrant to Purchase Stock | 8-K | 001-40656 | 4.1 | 12-12-2025 |
| 4.7 | Warrant Agent Agreement by and between Computershare Trust Company, N.A. and the Registrant | 10-Q | 001-40656 | 4.1 | 11-10-2025 |
| 10.1 | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. | S-1/A | 333-257820 | 10.1 | 7-26-2021 |
| 10.2+ | Amended and Restated 2016 Equity Incentive Plan and forms of agreement thereunder. | S-1/A | 333-257820 | 10.2 | 7-26-2021 |
| 10.3+ | 2021 Equity Incentive Plan and forms of agreements thereunder. | 10-K | 001-40656 | 10.2 | 3-23-2022 |
| 10.4+ | 2021 Employee Stock Purchase Plan and forms of agreements thereunder. | S-1/A | 333-257820 | 10.4 | 7-26-2021 |
| 10.5+ | 2024 Inducement Equity Incentive Plan, as amended, and forms of agreements thereunder | 8-K | 001-40656 | 10.1 | 1-30-2026 |
| 10.6+ | Employment Letter between the Registrant and Faraz Ali, M.B.A. | S-1/A | 333-257820 | 10.5 | 7-26-2021 |
| 10.7+ | Employment Letter between the Registrant and Whittemore (Whit) Tingley, M.D., Ph.D. | S-1/A | 333-257820 | 10.8 | 7-26-2021 |
| 10.8+ | Employment Letter between the Registrant and Tomohiro Higa, M.B.A. | 10-K | 001-40656 | 10.10 | 3-10-2025 |
| 10.9+ | Executive Change in Control and Severance Plan. | 8-K | 001-40656 | 10.1 | 6-12-2023 |
| 10.10+ | Executive Incentive Compensation Plan. | S-1/A | 333-257820 | 10.13 | 7-26-2021 |
| 10.11+* | Outside Director Compensation Policy. | ||||
| 10.12 | Lease between HCP Oyster Point III LLC and the Registrant dated as of September 6, 2016. | S-1/A | 333-257820 | 10.10 | 7-26-2021 |
| 10.13 | First Amendment to Lease between HCP Oyster Point III LLC and the Registrant dated as of September 6, 2016. | 10-Q | 001-40656 | 10.1 | 8-8-2024 |
| 10.14 | Lease between Terreno Park Union City LLC and the Registrant dated as of February 12, 2021. | S-1/A | 333-257820 | 10.11 | 7-26-2021 |
| 10.15 | Loan and Security Agreement by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company and Tenaya Therapeutics, Inc. | S-3 | 333-266741 | 1.2 | 8-10-2022 |
| 10.16 | Sales Agreement, dated August 10, 2022, by and between Tenaya Therapeutics, Inc. and SVB Securities LLC | S-3 | 333-266741 | 1.2 | 8-10-2022 |
| 19.1 | Insider Trading Policy | 10-K | 001-40656 | 19.1 | 3-10-2025 |
| 23.1* | Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm. | ||||
| 24.1* | Power of Attorney (included on the signature page to this Annual Report on Form 10-K). | ||||
| 31.1* · Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||
|---|---|---|---|---|---|
| 32.1†* · Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||
| 97 | Compensation Recovery Policy. | 10-K | 001-40656 | 97 | 3-18-2024 |
| 101.INS* | Inline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | ||||
| 104* | Cover page formatted as Inline XBRL and contained in Exhibit 101 | ||||
*Filed herewith.
- Management contract, compensatory plan or agreement.
† The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.